Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and who received tislelizumab plus eribulin treatment and achieved excellent efficacy. To our knowledge, this study is the first attempt to present tislelizumab in combination with eribulin for mTNBC treatment. New treatments resulting in prolonged survival and durable clinical responses would benefit mTNBC patients. Then, we summarize the possible influencing factors of the interaction between tislelizumab and eribulin.

Background: Pharyngeal packs are employed to mitigate postoperative nausea and vomiting (PONV) and have become prevalent in dental and otolaryngological surgeries. However, their clinical efficacy continues to be a topic of debate. The objective of the present study was to conduct a quantitative assessment of the impact of pharyngeal packing in dental and otolaryngological surgeries through meta-analysis. Methods: We identified relevant randomized controlled trials (RCTs) through systematic searches of online databases, including PubMed, Embase, and Cochrane Central. Potential eligible studies were evaluated using the Jadad scoring system (range 0-5 points), with only high-quality RCTs (3 points or more) being included. The incidence of PONV, morbidity, and the level of throat pain were aggregated and estimated. Publication bias was evaluated using funnel plot symmetry and the Egger test. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was utilized to rate the evidence. Results: Ten high-quality RCTs comprising 1026 participants were ultimately included. Subsequent quantitative pooled estimation unveiled that the utilization of pharyngeal packing did not lead to a significant reduction in the incidence of nausea (P = .272), vomiting (P = .775), overall PONV (P = .118), or throat pain (P = .149). By contrast, the application of pharyngeal packs was found to significantly increase the level of throat pain (P = .003). No obvious publication bias was detected, and the majority of evidence was rated high or moderate. Conclusion: Based on the existing evidence, we conclude that pharyngeal packing lacks clinical benefit and is not advised for dental and otolaryngological surgeries.

OBJECTIVES:Diode laser represents a practical clinical strategy for treating gingival hyperpigmentation. However, its effectiveness remains controversial. The aim of this meta-analysis was to evaluate the quantitative effects of diode laser therapy on gingival hyperpigmentation. METHOD AND MATERIALS:PubMed, Embase, Web of Science, and Cochrane Library were systematically searched for the use of diode laser in gingival hyperpigmentation. The primary outcomes assessed were the Dummett-Gupta Oral Pigmentation Index (DOPI), visual analog scale pain scores, and the Wound Healing Index (WHI) for overall evaluation. The I2 index was calculated to identify heterogeneity, and sensitivity analyses were performed to identify sources of heterogeneity. Funnel plots and the Egger test were utilized to evaluate publication bias. RESULTS:Thirteen randomized controlled trials involving a total of 233 participants were included in the study. The analysis demonstrated that diode laser had a significant effect on DOPI (standard mean difference [SMD] = -0.245, 95% CI -0.451 to -0.040, P = .019) and pain (SMD = -0.809, 95% CI -1.332 to -0.285, P = .002), with no significant effect on WHI (SMD = -0.224, 95% CI -1.100 to 0.653, P = .617). Despite the significant heterogeneity in VAS and WHI indicated by the I2 index statistic, the sensitivity analyses' results demonstrated the main findings' reliability. While no significant publication bias was detected for DOPI and WHI, the pain results exhibited notable publication bias. CONCLUSION:The study demonstrated that diode laser prolongs gingival repigmentation time and reduces pain compared to other treatments. However, efficacy in wound healing was not significantly affected.

The global ocean is undergoing gradual acidification and eutrophication which may have significant impacts on macroalgal communities. However, little is known regarding the interactive effects of ocean acidification (OA) and nitrate on Ulva lactuca, a primary producer widely distributed in coastal waters. This study focuses on the possible interactive effects of OA and elevated nitrate levels on physiological parameters of U. lactuca. Higher nitrate levels may increase growth, photosynthesis, respiration, pigment synthesis, Fv/Fm and Effective Quantum Yield, whereas CO2 enrichment may result in a reduction in photosynthesis, pigment content, Fv/Fm and Effective Quantum Yield. Higher nitrate levels increase NO3- uptake rate and nitrate reductase activity, which are further amplified by elevated CO2 levels. However, the stimulation of high nitrate towards pigment synthesis and photosynthesis is negatively affected by elevated CO2 levels. Our results suggest that U. lactuca could potentially increase its biomass in coastal eutrophic waters, and OA in the future is not expected to promote the growth of U. lactuca, but it can enhance its potential biofiltration to remove nitrate from coastal ecosystems.

Review question / Objective: Our study aimed to determine the role of gastric aspiration in the amelioration of postoperative vomiting (POV) by a meta-analysis. Eligibility criteria: The trials were considered for inclusion if they met the following criteria: (1) randomized controlled trial, (2) trials investigating the effects on reducing vomiting in oral and maxillofacial surgeries, (3) descriptions of postoperative vomiting as the main outcome, and (4) full English text.The following criteria were regarded as exclusion criteria: (1) non-RCTs, (2) investigations on other surgeries, (3) trials with insufficient raw data, (4) no full English text, and (5) irrelevant studies, reviews, comments and editorials.

BACKGROUND:We aimed to demonstrate the regulatory effect of long non-coding RNA (lncRNA) ENAH-202 on oral squamous cell carcinoma (OSCC) development as well as its molecular mechanism.METHODS:We detected ENAH-202 expression in OSCC tissues and cell lines by quantitative real-time PCR (qPCR). The biological function of ENAH-202 was assessed in vitro and in vivo using CCK-8, colony formation assays, transwell assays, xenograft formation, and tail vein injection. The further molecular mechanism by which ENAH-202 promoted OSCC progression was identified using RNA pull-down, LS-MS/MS analysis, RNA immunoprecipitation (RIP), and chromatin immunoprecipitation (ChIP) assays.RESULTS:ENAH-202 was significantly upregulated in OSCC tissues and cells. ENAH-202 promoted OSCC cell proliferation, migration, and invasion in vitro and in vivo. The expression of enabled homolog (ENAH) and epithelial-to-mesenchymal transition (EMT)-related proteins was changed with the expression of ENAH-202. Moreover, ENAH-202 promoted the transcription of Vimentin (VIM) by binding with ZNF502, which can help ENAH-202 promote OSCC progression.CONCLUSIONS:ENAH-202 facilitated OSCC cell proliferation and metastasis by regulating ZNF502/VIM axis, which played an important role in OSCC progression.

目的 将预防腹腔镜手术患者术中非计划性低体温的最佳证据应用于临床并评价其效果,为临床医护人员提供参考.方法 根据最佳证据,制订8条审查指标并开展证据应用.证据应用前后各纳入腹腔镜手术患者 30 例及 40 名手术室护士作为研究对象,比较最佳证据应用前后腹腔镜手术患者术中非计划性低体温的发生率、手术室护士对腹腔镜手术患者术中非计划性低体温的预防及管理的认知水平以及手术室护士依据证据采取预防低体温措施的执行率.结果 证据应用后,通过临床审查,腹腔镜手术患者术中非计划性低体温的发生率由证据应用前的33.3%降至证据应用后的 10.0%,手术室护士对腹腔镜手术患者术中非计划性低体温的预防及管理的认知水平合格率由证据应用前的 62.5%上升至证据应用后的 95.0%.证据应用前,对审查指标 6的执行率为90.0%,审查指标7的执行率为 70.0%,其余审查指标的执行率均在70.0%以下;最佳证据应用后,审查指标1、2、3、4、5、7、8的执行率均有明显提高,与应用前比较,差异具有统计学意义(P＜0.05).结论 预防腹腔镜手术患者术中非计划性低体温最佳证据的临床应用可降低患者术中非计划性低体温的发生率,提高手术室护士对腹腔镜手术患者术中非计划性低体温的预防及管理的认知水平及依据证据采取预防低体温措施的执行率.

N7-methylguanosine (m7G) modification is closely related to the occurrence of tumors. However, the m7G modification of circRNAs in oral squamous cell carcinoma (OSCC) remains to be investigated. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) was used to measure the methylation levels of m7G and identify m7G sites in circRNAs in human OSCC and normal tissues. The host genes of differentially methylated and differentially expressed circRNAs were analyzed by Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, and circRNA-miRNA-mRNA networks were predicted using the miRanda and miRDB databases. The analysis identified 2348 m7G peaks in 624 circRNAs in OSCC tissues. In addition, the source of m7G-methylated circRNAs in OSCC was mainly the sense overlap region compared with normal tissues. The most conserved m7G motif in OSCC tissues was CCUGU, whereas the most conserved motif in normal tissues was RCCUG (R = G/A). Importantly, GO enrichment and KEGG pathway analysis showed that the host genes of differentially methylated and differentially expressed circRNAs were involved in many cellular biological functions. Furthermore, the significantly differentially expressed circRNAs were analyzed to predict the circRNA-miRNA-mRNA networks. This study revealed the whole profile of circRNAs of differential m7G methylation in OSCC and suggests that m7G-modified circRNAs may impact the development of OSCC.

Background and purpose: Oral squamous cell carcinoma (OSCC) is the most common subtype of head and neck squamous cell carcinoma (HNSCC), and its pathogenesis is unclear. Nucleolar protein 8 (NOL8), as one of the RNA-binding protein (RBP), plays a key role in the occurrence and development of many kinds of tumors, however its role in OSCC is not clear. This study aimed to investigate the expression level of NOL8 in OSCC and its effects on the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of OSCC. Methods: The expression of NOL8 in HNSCC was analyzed online by gene expression profiling interactive analysis 2 (GEPIA2), tumor immune estimation resource (TIMER), the University of Alabama at Birmingham cancer data analysis portal (UALCAN) and the encyclopedia of RNA interactomes (ENCORI). The mRNA expression level of NOL8 in OSCC cells was detected by real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR). siRNA interference technique was used to knock down the expression of NOL8 in CAL-27 cells to form NOL8 knockdown group (si-NOL8-1, si-NOL8-2) and negative control group. CAL-27 and HN6 cells were overexpressed with NOL8 by lentivirus transfection technique to form NOL8 overexpression group and negative control group. Cell counting kit-8 (CCK-8) assay, scratch healing assay and transwell assay were used to detect the effect of NOL8 expression on the proliferation, migration and invasion of OSCC cells. Western blot assay was used to detect the effect of NOL8 on the expression of EMT-related genes including E-cadherin, vimentin and N-cadherin. The effect of NOL8 on the proliferation of OSCC cells in vivo was examed by xenograft formation assays. Results: The online analysis of GEPIA2, TIMER, UALCAN and ENCORI showed that the expression of NOL8 was higher in HNSCC than in normal tissues, and the expression of NOL8 in OSCC was significantly higher than in normal control cells. The relative expression of NOL8 in CAL-27 cells transfected with si-NOL8-1 and si-NOL8-2 was significantly lower compared with the negative control group. The results of CCK-8 assay, scratch healing assay and transwell assay showed that the proliferative ability, cell migration rate and invasion number of CAL-27 cells were significantly decreased after knockdown of NOL8 expression. The relative expression of NOL8 in CAL-27 and HN6 cells transfected with NOL8 was significantly higher compared with the control group. The proliferative ability, cell migration rate and invasion number of CAL-27 and HN6 cells in the overexpression NOL8 group were significantly higher compared with the negative control group. The results of Western blot showed that in CAL-27 cells, the expression of E-cadherin increased and the expressions of N-cadherin and vimentin decreased after NOL8 knockdown, while in CAL-27 and HN6 cells, the expression of E-cadherin decreased and the expressions of N-cadherin and vimentin increased after NOL8 overexpression. The xenograft formation assays showed that the weight of tumor was significantly higher in NOL8 overexpression group than in NOL8 control group. Conclusion: NOL8 is highly expressed in OSCC and can promote the proliferation, migration and invasion of OSCC, which may be related to the process of EMT.

Background: Internal N7-methylguanosine (m7G) methylation in mammalian messenger RNAs (mRNAs) is essential in disease development. However, the status of internally m7G-modified mRNAs in oral squamous cell carcinoma (OSCC) remains poorly understood. Methods: Methylated RNA immunoprecipitation sequencing (MeRIP-seq) was used to identify the m7G modification level of mRNAs and the expression of mRNAs between OSCC and normal tissues. These differentially methylated and expressed genes were subjected to Gene Ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and construction of protein-protein interaction (PPI) networks. Quantitative real-time PCR (qPCR) assay was performed to detect the expression of Baculoviral IAP Repeat Containing 3 (BIRC3) in vitro. The biological function of BIRC3 in OSCC was clarified using CCK-8, Transwell migration and Western blot assays. Results: The m7G-mRNA profile showed 9514 unique m7G peaks within 7455 genes in OSCC tissues. In addition, the most conserved m7G motif within mRNAs in OSCC was GGARG (R = G/A). The identified m7G peaks were mainly distributed in the coding sequence region within mRNAs in OSCC. GO enrichment and KEGG pathway analyses showed that m7G-modified genes were closely related to cancer progression. m7G-modified hub genes were screened from the constructed PPI networks. Furthermore, BIRC3 with high m7G methylation showed high expression in OSCC cell lines, as confirmed by qPCR assay. Functionally, the knockdown of BIRC3 significantly inhibited the proliferation and migration ability of CAL-27 cells in vitro functional assays. In addition, the relative expression of E-cadherin expression was elevated, while Vimentin and N-cadherin protein expression was decreased in CAL-27 cells transfected with si-BIRC3. This study suggests that BIRC3 could promote OSCC proliferation and migration, which may be associated with involvement in epithelial-mesenchymal transition (EMT) progression. Conclusions: This paper constructed a transcriptome map of internal m7G in mRNAs, which provides potential research value to study the role of m7G methylation in OSCC.

Pregnancy complicated with acute aortic dissection is rare and the mortality rate is high. The author reviewed the intraoperative nursing plan of a patient with aortic dissection in the third trimester of pregnancy who underwent Bentall operation and cesarean section, and introduced the evidence-based methods of preoperative nursing and nursing measures to prevent the complications that may occur in the perioperative period. Including preoperative preheat preservation, prevention of perioperative pressure injury, postoperative observation of cesarean section, intraoperative temperature regulation of Bentall, which can provide a reference for the clinical nursing measures of similar patients.

Afatinib, the world's first irreversible ErbB family (containing four different cancer cell epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a second-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It can be used as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with an EGFR-sensitive mutation or for patients with locally advanced or metastatic squamous lung cancer whose disease progresses during or after platinum-containing chemotherapy. Currently, with the use of third-generation EGFR-TKIs, afatinib is no longer clinically indicated as the first choice for patients with NSCLC who have EGFR-sensitive mutations. However, afatinib showed a considerable inhibitory effect in NSCLC patients with uncommon EGFR mutations (G719X, S768I, and L861Q) according to a combined post hoc analysis of the LUX-Lung2/3/6 trials. With the development of genetic testing technology, the detection rate of uncommon EGFR mutations is increasing. The aim of this paper is to describe in detail the sensitivity of rare EGFR mutations to afatinib and to provide information and a reference for those suffering from advanced NSCLC who have uncommon EGFR mutations.

Circulating tumor DNA (ctDNA) has contributed immensely to the management of hematologic malignancy and is now considered a valuable detection tool for solid tumors. ctDNA can reflect the real-time tumor burden and be utilized for analyzing specific cancer mutations via liquid biopsy which is a non-invasive procedure that can be used with a relatively high frequency. Thus, many clinicians use ctDNA to assess minimal residual disease (MRD) and it serves as a prognostic and predictive biomarker for cancer therapy, especially for non-small cell lung cancer (NSCLC). Advanced methods have been developed to detect ctDNA, and recent clinical trials have shown the rationality and feasibility of ctDNA for identifying mutations and guiding treatments in NSCLC. Here, we have reviewed recently developed ctDNA detection methods and the importance of sequence analyses of ctDNA in NSCLC.

Abstract Background The prognosis difference based on the depth of tumor muscularis propria invasion in gastric cancer (GC) was still debated, and therapy strategy for stage IB GC patient required further investigation. Methods A total of 380 patients with pT2 GC after radical surgery were retrospectively analyzed, including 185 in superficial muscularis propria (sMP) group and 195 in deep muscularis propria (dMP) group. Results The overall survival (OS) was significantly better for patients in sMP group than for patients in dMP group (P = 0.007). In multivariate analysis, depth of tumor invasion, pN stage, age, primary location, positive expression of p53, elevated maximal LDH, elevated initial CA19-9 and AFP level were independent prognostic factors for OS. The sMP group had a significantly better OS than dMP group (P = 0.014) in pN0 stage. After further stratification, the survival outcomes were not significantly different between deep muscularis propria tumor invasion without lymph node metastasis (dMPN0) group (stage IB) and superficial muscularis propria tumor invasion with stage 1–2 lymph node metastasis (sMPN1–2) group (stage II) (P = 0.100). Patients with adjuvant chemotherapy had a statistically better survival than those without in dMPN0 group (P = 0.045) and dMPN0 patients with adjuvant chemotherapy had better OS than sMPN1–2 patients (P = 0.015). In addition, greater postoperative survival could be observed in sMPN0 patients than dMPN0 patients in p53-positive group (P = 0.002), and similar OS could be seen between dMPN0 patients with p53-positive and T2N1–2 patients (P = 0.872). Conclusion As a unique subclassification of stage IB GC, appropriate adjuvant chemotherapy should be considered for patients with dMPN0 stage. In addition, positive expression of p53, elevated LDH could be potential factors in identifying the different prognoses for stage IB GC patients.

Background: Alectinib is a second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs), which has attracted much attention in the treatment of ALK-positive non-small cell lung cancer (NSCLC). At present, there are few reports on the efficacy and safety of alectinib in Chinese population. Moreover, biomarkers reflecting prognosis and efficacy are exceedingly needed. This study assessed the efficacy of alectinib in patients with ALK-positive NSCLC and analyzed the prognostic factors.Methods: Patients with ALK-positive NSCLC who were confirmed by histopathology or cytology at the Affiliated Cancer Hospital of Nanjing Medical University between October 2018 and October 2021 were enrolled. All patients were treated with alectinib. The clinical characteristics and circulating tumor biomarkers before and after treatment were collected. Kaplan-Meier test was used to calculate the progression-free survival (PFS). Univariate and multivariate Cox regression analyses were used to explore the influencing factors on PFS. Incidence of adverse events was observed.Results: Twenty patients progressed after first-line treatment (n=59) with alectinib, and 21 patients progressed following second-line treatment (n=36) with alectinib. The median PFS of first-line treatment patients was not achieved, and the median PFS of patients undergoing second-line treatment was 15.0 months [95% confidence interval (CI): 0.00-32.23]. The most common adverse reactions were liver dysfunction (37.50%), anemia (37.50%), and constipation (20.83%). The incidence of grade III and above adverse reactions was 6.25%. Univariate analysis showed that neutrophil-to-lymphocyte ratio [NLR; hazard ratio (HR) =0.424, P=0.005] carcinoembryonic antigen (CEA; HR =0.482, P=0.0 29), lactate dehydrogenase (LDH; HR =0.327, P=0.000), carbohydrate antigen (CA)199 (HR =0.313, P=0.002), and circulating cell free DNA (cfDNA; HR =0.229, P=0.008) concentration levels were associated with PFS, and multivariate analysis showed that NLR (HR =3.058, P=0.034) was independent prognostic factor. After three months of treatment, CEA, CA199, NLR, and LDH, could further predict the prognosis of alectinib treatment. Conclusions: The efficacy and safety of alectinib as a first-line or second-line treatment for ALK-positive NSCLC in keeping with published prospective studies. CEA, CA199, NLR, and LDH within the normal range after three months of treatment were associated with good prognosis. Detection of serum tumor markers can indicate therapeutic success in patients treated with alectinib.

目的 评价奥西替尼二线治疗表皮生长因子受体(EGFR)突变型晚期非小细胞肺癌(NSCLC)的疗效,对治疗前转移部位、耐药后进展部位与疗效间的关系进行探讨.方法 收集2017年1月1日至2019年1月1日67例经1～2代EGFR-酪氨酸激酶抑制剂(EGFR-TKI)治疗和50例一线化疗后进展的晚期NSCLC患者.全组患者均存在EGFR外显子20 T790M突变阳性,均给予奥西替尼(80 mg口服,每天1次)治疗直至疾病进展或出现不可耐受的不良反应;分析总体及不同亚组间患者的疗效.结果 截至2020年10月31日,117例奥西替尼受试者中有28例仍服用奥西替尼,用药最长时间达43.2个月;治疗后进展89例,其中45例死亡.全组中位无进展生存期(PFS)达15.2(95％CI:12.352～18.114)个月,中位总生存期(OS)未达.亚组分析显示,性别、一线治疗方案和治疗前转移病灶部位与PFS有关(P<0.05);一线治疗方案、EGFR突变类型和治疗前原发灶外转移类型与OS有关(P<0.05).存在肺内转移、胸膜转移、胸水肿瘤脱落细胞、肝转移、淋巴结转移和骨转移均会缩短受试者的中位PFS(P<0.05),存在肺内转移、淋巴结转移、肝转移和骨转移会缩短受试者的中位OS(P<0.05).进展病灶部位不同的受试者在中位PFS和死亡比例上也存在差异,但无统计学意义(P>0.05),其中以骨转移为进展部位的患者死亡比例最高(75.0％),而肾上腺转移出现进展的患者中位PFS最短(7.1个月).结论 奥西替尼对EGFR突变阳性晚期NSCLC患者二线治疗表现出良好的疗效.一线治疗使用EGFR-TKI序贯奥西替尼比一线化疗序贯奥西替尼治疗的PFS更长,治疗前肺内与肺外均有转移者预后不良,进展部位对疗效的影响有限.

Background: This study sought to implement evidence-based nursing practices for patients undergoing laparoscopy surgery to prevent unplanned hypothermia, to develop review indicators for evidence-based nursing practices, and to analyze obstacles and contributing factors. Methods: Using the Joanna Briggs Institute health care model as the evidence-based theoretical framework, clinical problems were identified, evidence was systematically researched, evaluated and summarized, an index and method of examination was established, and quality items were examined. According to the results of the baseline review, the obstacles and promoting factors were analyzed, and methods and countermeasures were developed. Results: This study summarized 15 pieces of best evidence in relation to the following 5 aspects: risk assessment, body temperature monitoring, ambient temperature, passive insulation, and active insulation. There were 11 quality review indicators, only 4 of which had compliance rates of 100%. The main obstacle factors were a lack of nursing norms and operating procedures, a lack of information, and a lack of motivation among nursing staff. Conclusions: Based on the best evidence and the professional judgment of clinical staff, the quality review index is scientific and implementable. In the application of this clinical evidence, obstacles and other factors should be solved to promote the transformation of evidence.

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is the leading cause of cancer-related death. Despite advances in chemotherapy and immunotherapy, the prognosis for advanced patients remains poor. The discovery of oncogenic driver mutations, such as anaplastic lymphoma kinase (ALK) mutations, means that a subset of patients has opportunities for targeted therapy. With the improvement of genetic testing coverage, more and more ALK fusion subtypes and ALK partners have been discovered, and more than 90 rare ALK fusion subtypes have been found in NSCLC. However, unlike the common fusion, echinoderm microtubule-associated protein-like 4 (EML4)-ALK, some rare ALK fusions such as striatin (STRN)-ALK and huntingtin interacting protein 1 (HIP1)-ALK, etc., the large-scale clinical data related to its efficacy are still immature. The clinical application of ALK-tyrosine kinase inhibitors (ALK-TKIs) mainly depends on the positivity of the ALK gene, regardless of the molecular characteristics of the fusion partner. Recent clinical studies in the ALK-positive NSCLC population have demonstrated differences in progression-free survival (PFS) among patients based on different ALK fusion subtypes. This article will introduce the biological characteristics of ALK fusion kinase and common detection methods of ALK fusion and focus on summarizing the differential responses of several rare ALK fusions to ALK-TKIs, and propose corresponding treatment strategies, so as to better guide the application of ALK-TKIs in rare ALK fusion population.